Carracedo A., Cantley L. C., Pandolfi P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat Rev Cancer. 2013 Apr; 13(4):227–32. Epub 2013 Feb 28. doi:10.1038/nrc3483.
Christofferson, T. Tripping over the truth: how the metabolic theory of cancer is overturning one of medicine’s most entrenched paradigms. White River Junction, VT: Chelsea Green Publishing; 2017.
Dalla Via L., et al. Mitochondrial permeability transition as target of anticancer drugs. Curr Pharm Des. 2014; 20(2):223–44. Epub 2013 May 16. Davila A. F., Zamorano P. Mitochondria and the evolutionary roots of cancer. Phys Biol. 2013 Apr; 10(2):026008. Epub 2013 Mar 22. doi:10.1088/1478-3975/10/2/026008.
DeBerardinis R. J., et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007 Dec 4; 104(49):19345–50. doi:10.1073/pnas.0709747104.
DeBerardinis R. J., et al. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008 Jan; 7(1):11–20. doi:10.1016/j.cmet.2007.10.002.
Fantin V. R., St-Pierre J., Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006 Jun; 9(6):425–34. doi:10.1016/j.ccr.2006.04.023. Gottfried E., et al. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood. 2006 Mar 1; 107(5):2013–21. doi:10.1182/blood-2005-05-1795.
Gottlieb E., Tomlinson I. P. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer. 2005 Nov; 5(11):857–66. doi:10.1038/nrc1737.
He X., et al. Suppression of mitochondrial complex I influences cell metastatic properties. PLoS One. 2013 Apr 22; 8(4):e61677. doi:10.1371/ journal.pone.0061677.
Hoang B. X., et al. Restoration of cellular energetic balance with L-carnitine in the neurobioenergetic approach for cancer prevention and treatment. Med Hypotheses. 2007; 69(2): 262–72. doi:10.1016/j.mehy.2006.11.049. Hung W. Y., et al. Somatic mutations in mitochondrial genome and their potential roles in the progression of human gastric cancer. Biochim Biophys Acta. 2010 Mar; 1800(3):264–70. doi:10.1016/j.bba-gen.2009.06.006.
Ishikawa K., et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science. 2008 May 2; 320(5876):661–4. doi:10.1126/science.1156906.
Kiebish M. A., et al. Cardiolipin and electron transport chain abnormalities in mouse brain tumor mitochondria: lipidomic evidence supporting the Warburg theory of cancer. J Lipid Res. 2008 Dec; 49(12):2545–66. doi:10.1194/jlr.M800319-JLR200.
Kroemer G., Pouyssegur J. Tumor cell metabolism: cancer’s Achilles’ heel. Cancer Cell. 2008 Jun; 13(6):472–82. doi:10.1016/j.ccr.2008.05.005.
Kulawiec M., Owens K. M., Singh K. K. Cancer cell mitochondria confer apoptosis resistance and promote metastasis. Cancer Biol Ther. 2009 Jul; 8(14):1378–85.
Ladiges W., et al. A mitochondrial view of aging, reactive oxygen species and metastatic cancer. Aging Cell. 2010 Aug; 9(4):462–5. doi:10.1111/ j.1474–9726.2010.00579.x.
Lee H. C., Chang C. M., Chi C. W. Somatic mutations of mitochondrial DNA in aging and cancer progression. Ageing Res Rev. 2010 Nov; 9 Suppl 1:S47–S58. doi:10.1016/j.arr.2010.08.009.
Li X., et al. Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol. 2013 Feb 25; 6(1):19. Epub. doi:10.1186/1756-8722-6-19.
Lin C. C., et al. Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci Rep. 2012; 2:785. Epub 2012 Nov 8. doi:10.1038/srep00785.
Ma Y., et al. Mitochondrial dysfunction in human breast cancer cells and their transmitochondrial cybrids. Biochim Biophys Acta. 2010 Jan; 1797(1):29–37. doi:10.1016 /j.bbabio.2009.07.008.
Modica-Napolitano J. S., Kulawiec M., Singh K. K. Mitochondria and human cancer. Curr Mol Med. 2007 Feb; 7(1):121–31. doi:10.2174/156652 407779940495.
Nicolson G. L., Conklin K. A. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by molecular replacement therapy. Clin Exp Metastasis. 2008; 25(2):161–9. doi:10.1007/s10585-007-9129-z.
